EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Recent histone deacetylase inhibitors in cancer therapy

Roza Parveen, Divya Harihar, Biswa Prasun Chatterji iD

Cancer · 2023-11 · 129 (21) · 3372-3380

DOI: 10.1002/cncr.34974 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer, online erschienen am 10.08.2023. Verfasst von Roza Parveen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health Sciences, Tampere University, Tampere, Finland. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 174-mal zitiert (Crossref) und nennt 63 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer metastasis increases the complexity of the disease and escalates patient mortality. Traditional chemotherapy has been associated with low efficacy and marked side effects. Studies pivot toward histone deacetylase (HDAC) enzymes and inhibitors because they are critical for chromatin structure, gene regulation, and cellular activities that are linked to metastasis and cancer progression. HDAC inhibitors (HDACi) can alter gene expression patterns and can lead to cell‐cycle arrest and apoptosis in neoplastic cells. Several HDACi drugs like vorinostat, romidepsin, panobinostat, and belinostat are approved by the Food and Drug Administration. China and Japan have approved the use of tucidinostat, a new subtype‐selective HDACi that inhibits class 1 HDAC1, HDAC2, HDAC3, as well as class 2b HDAC10. These drugs have shown promising results in the treatment of multiple carcinoma including cervical cancer, T‐cell lymphoma, brain cancer, and breast cancer. This review highlights the HDACi classes, the mechanism of action of these inhibitors, their preclinical and clinical efficacy, and the latest clinical trials and patents used in cancer therapeutics. Overall, this review focuses on patents and clinical trials data from 2019 onward to give a better viewpoint on current trends in HDACis as chemotherapy agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histone Deacetylase InhibitorsNeoplasmsAntineoplastic AgentsHumansAnimalsClinical Trials as Topic

Stichwörter der Autor:innen

HDAC inhibitorsHDACi drugsPTCLcancercombinational therapypatents

Substanzen

Histone Deacetylase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Faculty of Medicine and Health Sciences, Tampere University, Tampere, Finland.
  • School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm, Sweden.
  • Faculty of Science, Assam Down Town University, Guwahati, India.

ORCID-Profile: Biswa Prasun Chatterji

Zitieren

APA

Parveen, R., Harihar, D., & Chatterji, B. P. (2023). Recent histone deacetylase inhibitors in cancer therapy. Cancer, 129(21), 3372-3380. https://doi.org/10.1002/cncr.34974

Vancouver

Parveen R, Harihar D, Chatterji BP. Recent histone deacetylase inhibitors in cancer therapy. Cancer. 2023;129(21):3372-3380. doi:10.1002/cncr.34974

BibTeX
@article{Parveen2023,
  author = {Parveen, Roza and Harihar, Divya and Chatterji, Biswa Prasun},
  title = {Recent histone deacetylase inhibitors in cancer therapy},
  journal = {Cancer},
  year = {2023},
  volume = {129},
  number = {21},
  pages = {3372--3380},
  doi = {10.1002/cncr.34974}
}
Kostenlos starten →